Pylera? (bismuth subcitrate potassium/metronidazole/tetracycline hydrochloride) in the eradication of Helicobacter pylori infection: a profile of its use in Europe

摘要

Abstract Pylera? comprises three (bismuth substrate potassium?+?metronidazole?+?tetracycline hydrochloride) of four components of bismuth-based quadruple therapy for the eradication of Helicobacter pylori (H. pylori) in a single capsule. The 10-day regimen consists of the relatively convenient administration of Pylera? four times daily?+?twice-daily administration of the proton pump inhibitor omeprazole. This regimen provides an effective, well tolerated and relatively convenient option for administering bismuth-based quadruple therapy, which a recommended first- and second-line treatment for H. pylori eradication. The Pylera? regimen effectively eradicated H. pylori, regardless of the treatment line, the resistance of the bacterial strain to metronidazole and/or clarithromycin, the type of gastric disease and the country of treatment. The regimen is well tolerated, with a tolerability profile that is consistent with those of the individual components taken separately.]]>